NICE Endorses Brilique at a Lower Dosage for Extended Treatment

August 18, 2016

The UK’s drug pricing watchdog is recommending reimbursement of AstraZeneca’s drug Brilique for patients with a previous history of heart attacks.

In draft guidance, the National Institute for Health and Care Excellence recommended that the drug be reimbursed at a lower dosage as a continuing treatment for patients who have suffered a heart attack within the past year and are at risk of further heart events.

Under the recommendation, patients would take 60 mg of Brilique in combination with aspirin twice daily.

View today's stories